Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Early Switch in Moderate ARDS (SWITCH-ARDS)

13 novembre 2026 mis à jour par: DEMOSTHENES MAKRIS, University of Thessaly

Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.

This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.

Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).

The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).

Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.

Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.

The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.

After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.

Type d'étude

Observationnel

Inscription (Estimé)

30

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Apostolos - Alkiviadis Menis, MD, PhD
  • Numéro de téléphone: +30 2413501280
  • E-mail: menis.ap.alk@proton.me

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Larissa, Grèce
        • Recrutement
        • Critical Care Department, University Hospital of Larisa
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).

La description

Inclusion Criteria:

  • Age ≥18 years
  • Endotracheally intubated and receiving invasive mechanical ventilation
  • Meets diagnostic criteria for acute respiratory distress syndrome
  • PaO₂/FiO₂ ratio >100 and ≤200 mmHg
  • Receiving controlled mechanical ventilation immediately before the transition trial

Exclusion Criteria:

  • Implanted electrical cardiac or other device incompatible with electrical impedance tomography
  • Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
  • Contraindication to placement of an esophageal balloon catheter
  • Active neuromuscular blockade at initiation of the transition trial
  • Significant hemodynamic instability
  • Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Experimental: Protocolized Transition to Assisted Mechanical Ventilation

Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Délai: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Délai: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Délai: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements.

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Délai: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs).

During the first thirty minutes of assisted ventilation.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Délai: During the first thirty minutes of assisted ventilation.

The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography.

During the first thirty minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Délai: During the first 30-minutes of assisted ventilation.

The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Délai: During the first 30-minutes of assisted ventilation.

The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Délai: During the first 30-minutes of assisted ventilation.

The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation
Délai: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation.
Délai: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Apostolos - Alkiviadis Menis, MD, PhD, General University Hospital of Larisa, University of Thessaly
  • Directeur d'études: Makris, MD, PhD, General University Hospital of Larisa, University of Thessaly

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 novembre 2026

Achèvement primaire (Estimé)

1 octobre 2028

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

8 septembre 2026

Première soumission répondant aux critères de contrôle qualité

23 octobre 2026

Première publication (Réel)

30 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SWITCH_MODERATE_ARDS

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .